CD8A and neoplasm: Of note, pembrolizumab plus SBRT increased the infiltration of CD8+ T cells, as well as those expressing CD103, more prominently than pembrolizumab alone in patients with metastatic NSCLC [144], suggesting that effects of RT on tumor-specific CD8+ T cells may enhance the anti-tumor activity of ICIs.